Countering Bioterrorism: Current Status and Challenges-A Focus on Pharmaceutical Products and Vaccines-
-
- Eto Akiko
- Department of Health Crisis Management, National Institute of Public Health
-
- Kanatani Yasuhiro
- Department of Health Crisis Management, National Institute of Public Health
抄録
Countermeasures against bioterrorism have increased since September 11 and anthrax attacks in the United States of America in 2001. The “Strategy to Make Japan the Safest Country in the World” was approved by the Cabinet in 2013. Strengthening countermeasures against naturally-occurring infectious disease outbreaks implies strengthening countermeasures against bioterrorism; however, the latter bears particular challenges. One of these challenges is the approval of counter-terrorism therapeutic or prophylactic agents, since the use of these agents is rare. To move up the market for innovative drug candidates, the “SAKIGAKE” designation scheme was introduced on a pilot basis by the Ministry of Health, Labour and Welfare in 2015. It is hoped that this scheme will be also applicable for counter-terrorism agents.
収録刊行物
-
- ADC Letter for Infectious Disease Control
-
ADC Letter for Infectious Disease Control 5 (2), 50-52, 2018
帝京大学 アジア国際感染症制御研究所
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390845713003093888
-
- NII論文ID
- 130007494426
-
- ISSN
- 24240907
- 21895171
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可